Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial — Masatoshi Kudo (2021) | RDL Network
Pembrolizumab demonstrated antitumor activity and was well tolerated in the Asian subgroup of KEYNOTE-240. A trend toward greater benefit with pembrolizumab in the Asian subgroup was observed compared with the overall cohort, supporting further evaluation of pembrolizumab treatment in this population.
Masatoshi Kudo, Ho Yeong Lim, Ann‐Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, N. Morimoto, K. Ohkawa, T. Yamashita, Ki Hoon Lee, E. Chen, A.B. Siegel, B-Y. Ryoo
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann‐Lii Cheng, Stephen L. Chan, T.W.C. Yau, Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martínez‐Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Cheng A.-L., Chan S.L., Yau T., Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Lim H.Y., Sadahisa Ogasawara, S. Cattan, Yee Chao, Siegel A.B., I. Martinez-Forero, Wei Z, Liu C.-C., Finn R.S.
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Cheng A.-L., Chan S.L., Yau T., Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Lim H.Y., Sadahisa Ogasawara, S. Cattan, Yee Chao, Siegel A.B., I. Martinez-Forero, Wei Z, Liu C.-C., Finn R.S.
Discussion(0)
No comments yet. Be the first to comment.